UCIBIO, REQUIMTE, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
UCIBIO, REQUIMTE, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal.
Int J Pharm. 2019 Jul 20;566:126-140. doi: 10.1016/j.ijpharm.2019.05.057. Epub 2019 May 23.
Topical drug delivery in the oral mucosa has its set of challenges due to the unique anatomical and physiological features of the oral cavity. As such, the outcomes of local pharmacological treatments in oral disorders can fail due to unsuccessfully drug delivery. Oral mucositis, a severe inflammatory and ulcerative side effect of oncological treatments, is one of such diseases. Although the damaged tissue is within reach, no approved topical drug treatment is available. Several strategies based on its physiopathology have been implemented and clinically used. Even so, results tend to lack or be insufficient to improve patient's quality of life. The use of corticosteroids has been employed in such strategies due to their strong anti-inflammatory action. Typically, these are administrated in simple liquid formulations, where the drug is dispersed or solubilized, lacking the ability to maintain local concentration. In this work, we propose the development of a biocompatible delivery system with boosted abilities of retention and control release of budesonide, a corticosteroid with an elevated ratio of topical anti-inflammatory to systemic action. Through spray-drying, polymeric particles of Chitosan and Eudragit® E PO were produced and characterized for the vectorization of this drug.
由于口腔独特的解剖学和生理学特征，口腔黏膜的局部药物输送存在一系列挑战。因此，由于药物输送不成功，口腔疾病的局部药物治疗效果可能会失败。口腔黏膜炎是一种严重的炎症性和溃疡性的肿瘤治疗副作用，就是这样一种疾病。尽管受损组织触手可及，但尚无批准的局部药物治疗方法。已经实施并在临床上使用了几种基于其病理生理学的策略。即便如此，结果往往缺乏或不足以提高患者的生活质量。由于其强大的抗炎作用，皮质类固醇已被用于这些策略中。通常，这些药物以简单的液体配方给药，其中药物被分散或溶解，缺乏维持局部浓度的能力。在这项工作中，我们提出了开发一种具有增强的布地奈德保留和控制释放能力的生物相容性输送系统的方法，布地奈德是一种具有较高的局部抗炎作用与全身作用比率的皮质类固醇。通过喷雾干燥，制备了壳聚糖和 Eudragit® E PO 的聚合物颗粒，并对该药物进行了载体化研究。
